jrnl1428

Publication Venue For

  • FcγRIIIa SNPs and haplotypes affect human IgG binding and association with lupus nephritis in African Americans. 2013
  • Editorial: Ethnic-specific genetic analyses in rheumatoid arthritis: Incremental gains but valuable contributions to the big picture.  65:3014-3016. 2013
  • Value of isolated IgA anti-β2-glycoprotein i positivity in the diagnosis of the antiphospholipid syndrome.  65:3186-3193. 2013
  • Headache in systemic lupus erythematosus: Results from a prospective, international inception cohort study.  65:2887-2897. 2013
  • Multiple lupus-associated ITGAM variants alter mac-1 functions on neutrophils.  65:2907-2916. 2013
  • 2013 Update of the 2011 American College of Rheumatology Recommendations for the treatment of juvenile idiopathic arthritis: Recommendations for the medical therapy of children with systemic juvenile idiopathic arthritis and tuberculosis screening among children receiving biologic medications.  65:2499-2512. 2013
  • Death receptor 5-targeted depletion of interleukin-23-producing macrophages, Th17, and Th1/17 associated with defective tyrosine phosphatase in mice and patients with rheumatoid arthritis.  65:2594-2605. 2013
  • Extension of the germinal center stage of B cell development promotes autoantibodies in BXD2 mice.  65:2703-2712. 2013
  • Association of granulomatosis with polyangiitis (Wegener's) with HLA-DPB1*04 and SEMA6A gene variants: Evidence grom genome-wide analysis.  65:2457-2468. 2013
  • Validation of the methotrexate-first strategy in patients with early, poor-prognosis rheumatoid arthritis: Results from a two-year randomized, double-blind trial.  65:1985-1994. 2013
  • Changes in lipoproteins associated with methotrexate or combination therapy in early rheumatoid arthritis: Results from the treatment of early rheumatoid arthritis trial.  65:1430-1438. 2013
  • Brief report: Incidence of selected opportunistic infections among children with juvenile idiopathic arthritis.  65:1384-1389. 2013
  • Protein kinase Cβ is required for lupus development in sle mice.  65:1022-1031. 2013
  • Epidemiology and sociodemographics of systemic lupus erythematosus and lupus nephritis among US adults with Medicaid coverage, 2000-2004.  65:753-763. 2013
  • Low-dose naltrexone for the treatment of fibromyalgia: Findings of a small, randomized, double-blind, placebo-controlled, counterbalanced, crossover trial assessing daily pain levels.  65:529-538. 2013
  • Valgus malalignment is a risk factor for lateral knee osteoarthritis incidence and progression: Findings from the multicenter osteoarthritis study and the osteoarthritis initiative.  65:355-362. 2013
  • Do radiographic disease and pain account for why people with or at high risk of knee osteoarthritis do not meet physical activity guidelines?.  65:139-147. 2013
  • Single-nucleotide polymorphisms in VKORC1 are risk factors for systemic lupus erythematosus in Asians.  65:211-215. 2013
  • Tumor necrosis factor α inhibitor therapy and cancer risk in chronic immune-mediated diseases.  65:48-58. 2013
  • Endothelial nitric oxide synthase inhibits the development of autoimmune-mediated vasculitis in mice.  64:4114-4124. 2012
  • Measurement of cell-bound complement activation products enhances diagnostic performance in systemic lupus erythematosus.  64:4040-4047. 2012
  • Vitamin D, race, and experimental pain sensitivity in older adults with knee osteoarthritis.  64:3926-3935. 2012
  • Association of two independent functional risk haplotypes in TNIP1 with systemic lupus erythematosus.  64:3695-3705. 2012
  • Impact of genetic ancestry and sociodemographic status on the clinical expression of systemic lupus erythematosus in American Indian-European populations.  64:3687-3694. 2012
  • Meta-analysis of genetic polymorphisms in granulomatosis with polyangiitis (Wegener's) reveals shared susceptibility loci with rheumatoid arthritis.  64:3463-3471. 2012
  • A randomized comparative effectiveness study of oral triple therapy versus etanercept plus methotrexate in early aggressive rheumatoid arthritis: The treatment of early aggressive rheumatoid arthritis trial.  64:2824-2835. 2012
  • Derivation and validation of the systemic lupus international collaborating clinics classification criteria for systemic lupus erythematosus.  64:2677-2686. 2012
  • Muscle density in rheumatoid arthritis: Associations with disease features and functional outcomes.  64:2438-2450. 2012
  • Prevalence, incidence, and demographics of systemic lupus erythematosus and lupus nephritis from 2000 to 2004 among children in the US medicaid beneficiary population.  64:2669-2676. 2012
  • Rates of hospitalized bacterial infection associated with juvenile idiopathic arthritis and its treatment.  64:2773-2780. 2012
  • Belimumab reduces autoantibodies, normalizes low complement levels, and reduces select B cell populations in patients with systemic lupus erythematosus.  64:2328-2337. 2012
  • Evaluation of TRAF6 in a large multiancestral lupus cohort.  64:1960-1969. 2012
  • Association of single-nucleotide polymorphisms in CCR6, TAGAP, and TNFAIP3 with rheumatoid arthritis in African Americans.  64:1355-1358. 2012
  • Impact of interactions of cigarette smoking with NAT2 polymorphisms on rheumatoid arthritis risk in African Americans.  64:655-664. 2012
  • Prescribing practices in a US cohort of rheumatoid arthritis patients before and after publication of the American College of Rheumatology treatment recommendations.  64:630-638. 2012
  • Systemic autoimmunity caused by fas deficiency in macrophages: A new perspective on the first identified autoimmunity gene.  64:609-612. 2012
  • Evidence for gene-gene epistatic interactions among susceptibility loci for systemic lupus erythematosus.  64:485-492. 2012
  • Developing a provisional definition of flare in patients with established gout.  64:1508-1517. 2012
  • Gene-gene interaction of BLK, TNFSF4, TRAF1, TNFAIP3, and REL in systemic lupus erythematosus..  64:222-231. 2012
  • NF-ATc1 levels are increased in murine and human lupus T cells: Comment on the article by kyttaris et al.  64:1294. 2012
  • Rates of malignancy associated with juvenile idiopathic arthritis and its treatment..  64:1263-1271. 2012
  • Treatment of arthritis by macrophage depletion and immunomodulation: testing an apoptosis-mediated therapy in a humanized death receptor mouse model..  64:1098-1109. 2012
  • Wnt signaling genes of murine chromosome 15 are involved in sex-affected pathways of inflammatory arthritis..  64:1057-1068. 2012
  • A phase III, randomized, placebo-controlled study of belimumab, a monoclonal antibody that inhibits B lymphocyte stimulator, in patients with systemic lupus erythematosus.  63:3918-3930. 2011
  • Identification of novel genetic susceptibility loci in African American lupus patients in a candidate gene association study.  63:3493-3501. 2011
  • A Novel Role for Vitamin D in Immunosenescence: Is Enough Too Much for Naive CD8 T Cells?.  63:S915-S916. 2011
  • Current Social Position Associated with Rheumatoid Arthritis Severity and Self-Reported Health Outcomes in African Americans.  63:S604-S604. 2011
  • Influence of Lifecourse Social Position on Rheumatoid Arthritis Disease Severity in African Americans..  63:S1039-S1039. 2011
  • Intra-Articular Infliximab Treatment of Refractory TMJ Arthritis in Children with JIA..  63:S103-S104. 2011
  • Recommendations for publication of genetic association studies in Arthritis & Rheumatism.  63:2839-2847. 2011
  • Reply.  63:3175-3177. 2011
  • Association of PPP2CA polymorphisms with systemic lupus erythematosus susceptibility in multiple ethnic groups.  63:2755-2763. 2011
  • Collagen-induced arthritis is exacerbated in C-reactive protein-deficient mice.  63:2641-2650. 2011
  • Dose escalation of certolizumab pegol from 200 mg to 400 mg every other week provides no additional efficacy in rheumatoid arthritis: An analysis of individual patient-level data.  63:2203-2208. 2011
  • Hospital volume and surgical outcomes after elective hip/knee arthroplasty: A risk-adjusted analysis of a large regional database.  63:2531-2539. 2011
  • Genetic analyses of interferon pathway-related genes reveal multiple new loci associated with systemic lupus erythematosus.  63:2049-2057. 2011
  • Inhibition of the catalytic function of activation-induced cytidine deaminase promotes apoptosis of germinal center B cells in BXD2 mice.  63:2038-2048. 2011
  • Fine-mapping and transethnic genotyping establish IL2/IL21 genetic association with lupus and localize this genetic effect to IL21.  63:1689-1697. 2011
  • Trends in the incidence, demographics, and outcomes of end-stage renal disease due to lupus nephritis in the US from 1995 to 2006.  63:1681-1688. 2011
  • Type i interferon-dependent CD86high marginal zone precursor b cells are potent T cell costimulators in mice.  63:1054-1064. 2011
  • Fluctuation of knee pain and changes in bone marrow lesions, effusions, and synovitis on magnetic resonance imaging.  63:691-699. 2011
  • Personalized medicine in rheumatoid arthritis: Miles to go before we sleep.  63:590-593. 2011
  • Anakinra as first-line disease-modifying therapy in systemic juvenile idiopathic arthritis: Report of forty-six patients from an international multicenter series.  63:545-555. 2011
  • Should bisphosphonates be used for long-term treatment of glucocorticoid-induced osteoporosis?.  63:325-328. 2011
  • The incidence of gastrointestinal perforations among rheumatoid arthritis patients.  63:346-351. 2011
  • Autoimmune-mediated reduction of high-density lipoprotein-cholesterol and paraoxonase 1 activity in systemic lupus erythematosus-prone gld mice.  63:201-211. 2011
  • End-stage renal disease due to lupus nephritis among children in the US, 1995-2006.  63:1988-1997. 2011
  • A functional RANKL polymorphism associated with younger age at onset of rheumatoid arthritis.  62:2864-2875. 2010
  • Generalized bone loss as a predictor of three-year radiographic damage in African American patients with recent-onset rheumatoid arthritis.  62:2219-2226. 2010
  • Prolonged expression of CD154 on CD4 T cells from pediatric lupus patients correlates with increased CD154 transcription, increased nuclear factor of activated T cell activity, and glomerulonephritis.  62:2499-2509. 2010
  • Rheumatoid arthritis risk allele PTPRC is also associated with response to anti-tumor necrosis factor α therapy.  62:1849-1861. 2010
  • Reply.  62:1837-1838. 2010
  • Antimalarial treatment may have a time-dependent effect on lupus survival: Data from a multinational Latin American inception cohort.  62:855-862. 2010
  • Effects of teriparatide versus alendronate for treating glucocorticoid-induced osteoporosis: Thirty-six-month results of a randomized, double-blind, controlled trial.  60:3346-3355. 2009
  • Epitope-specific immunotherapy of rheumatoid arthritis: Clinical responsiveness occurs with immune deviation and relies on the expression of a cluster of molecules associated with T cell tolerance in a double-blind, placebo-controlled, pilot phase II trial.  60:3207-3216. 2009
  • The FCRL3 -169CT promoter single-nucleotide polymorphism, which is associated with systemic lupus erythematosus in a Japanese population, predicts expression of receptor protein on CD19+ B cells.  60:3510-3512. 2009
  • Questioning the likelihood that sodium oxybate can be used to successfully treat fibromyalgia: Comment on the article by Russell et al.  60:2854. 2009
  • Risk factors and impact of recurrent lupus nephritis in patients with systemic lupus erythematosus undergoing renal transplantation: Data from a single US institution.  60:2757-2766. 2009
  • A polymorphism within IL21R confers risk for systemic lupus erythematosus.  60:2402-2407. 2009
  • Methotrexate catabolism to 7-hydroxymethotrexate in rheumatoid arthritis alters drug efficacy and retention and is reduced by folic acid supplementation.  60:2257-2261. 2009
  • Variants within MECP2, a key transcription regulator, are associated with increased susceptibility to lupus and differential gene expression in patients with systemic lupus erythematosus.  60:1076-1084. 2009
  • Meniscal tear in knees without surgery and the development of radiographic osteoarthritis among middle-aged and elderly persons: The multicenter osteoarthritis study.  60:831-839. 2009
  • For Whom Does Bone Mineral Density Measurement Enhance Fracture Risk Evaluation? Application of the WHO Fracture Risk Assessment Tool (FRAX) to African Americans with Early Rheumatoid Arthritis.  58:4010-4011. 2008
  • Reply.  58:3635-3636. 2008
  • Association of body fat with C-reactive protein in rheumatoid arthritis.  58:2632-2641. 2008
  • Associations of education and income with health status outcomes in African-Americans (AAs) with early rheumatoid arthritis (RA).  58:S860-S861. 2008
  • Association of plasma B lymphocyte stimulator levels and disease activity in systemic lupus erythematosus.  58:2453-2459. 2008
  • Klinefelter's syndrome (47,XXY) in male systemic lupus erythematosus patients: Support for the notion of a gene-dose effect from the X chromosome.  58:2511-2517. 2008
  • Systemic lupus international collaborating clinics renal activity/response exercise: Comparison of agreement in rating renal response.  58:1789-1795. 2008
  • Systemic lupus international collaborating clinics renal activity/response exercise: Development of a renal activity score and renal response index.  58:1784-1788. 2008
  • The HLA-DRB1 shared epitope in Caucasians with rheumatoid arthritis: A lesson learned from tic-tac-toe.  58:1211-1215. 2008
  • High prevalence of temporomandibular joint arthritis at disease onset in children with juvenile idiopathic arthritis, as detected by magnetic resonance imaging but not by ultrasound.  58:1189-1196. 2008
  • Autoantibodies and neuropsychiatric events at the time of systemic lupus erythematosus diagnosis: Results from an international inception cohort study.  58:843-853. 2008
  • Dawn of the era of biologics in the treatment of the rheumatic diseases.  58. 2008
  • The HLA-DRB1 shared epitope is associated with susceptibility to rheumatoid arthritis in African Americans through European genetic admixture.  58:349-358. 2008
  • Drug-specific and time-dependent risks of bacterial infection among patients with rheumatoid arthritis who were exposed to tumor necrosis factor α antagonists.  56:4226-4227. 2007
  • Effect of meniscal damage on the development of frequent knee pain, aching, or stiffness.  56:4048-4054. 2007
  • Premature atherosclerosis in systemic lupus erythematosus: Comment on the article by Westerweel et al [10].  56:3878-3879. 2007
  • Variation in the relative copy number of the TLR7 gene in patients with systemic lupus erythematosus and healthy control subjects.  56:3375-3378. 2007
  • Correlation of the development of knee pain with enlarging bone marrow lesions on magnetic resonance imaging.  56:2986-2992. 2007
  • Clinical and genetic risk factors for pneumonia in systemic lupus erythematosus.  56:2679-2686. 2007
  • Reply [4].  56:2812. 2007
  • Risk of serious bacterial infections among rheumatoid arthritis patients exposed to tumor necrosis factor α antagonists.  56:1125-1133. 2007
  • Accelerated damage accrual among men with systemic lupus erythematosus XLIV. Results from a multiethnic US cohort.  56:622-630. 2007
  • Systemic lupus erythematosus in a multiethnic US cohort XLIII. The significance of thrombocytopenia as a prognostic factor.  56:614-621. 2007
  • Neuropsychiatric events at the time of diagnosis of systemic lupus erythematosus: An international inception cohort study.  56:265-273. 2007
  • Association of a transmembrane polymorphism of Fcγ receptor IIb (FCGR2B) with systemic lupus erythematosus in Taiwanese patients.  54:3908-3917. 2006
  • Citrullinated proteins in rheumatoid arthritis: Crucial... but not sufficient!.  54:3381-3389. 2006
  • Patients with juvenile psoriatic arthritis comprise two distinct populations.  54:3564-3572. 2006
  • Anti-cyclic citrullinated peptide (CCP) antibody and rheumatoid factor (RF) isotypes in African Americans with early rheumatoid arthritis: Results from the CLEAR registry..  54:S189-S189. 2006
  • Anti-cyclic citrullinated peptide antibody and rheumatoid factor isotypes in African Americans with early rheumatoid arthritis.  54:3057-3059. 2006
  • Genetic and non-genetic factors associated with baseline radiographic erosions in African-Americans with early rheumatoid arthritis: Results from the CLEAR registry..  54:S401-S401. 2006
  • Genetic and non-genetic risk factors associated with rheumatoid arthritis susceptibility in African-Americans: Results from the CLEAR registry..  54:S400-S401. 2006
  • Novel association of a functional single nucleotide polymorphism in the BTNL2 gene with susceptibility to rheumatoid arthritis and baseline radiographic severity in African-Americans independent of HLA DRB1: Results from the CLEAR registry..  54:S391-S391. 2006
  • Soluble human p55 and p75 tumor necrosis factor receptors reverse spontaneous arthritis in transgenic mice expressing transmembrane tumor necrosis factor α.  54:2872-2885. 2006
  • The HLA DRB1 shared epitope is associated with rheumatoid arthritis in African-Americans and correlates with higher estimated admixture of European ancestry: Results from the CLEAR registry..  54:S392-S392. 2006
  • Mortality in systemic lupus erythematosus.  54:2550-2557. 2006
  • Homocysteine levels and disease duration independently correlate with coronary artery calcification in patients with systemic lupus erythematosus.  54:2220-2227. 2006
  • Association of antioxidized low-density lipoprotein antibodies with vascular arterial events and renal manifestations in systemic lupus erythematosus patients: Comment on the article by Frostegård et al [6].  54:2035-2036. 2006
  • Systemic lupus erythematosus in a multiethnic US cohort: XXXIV. Deficient mannose-binding lectin exon 1 polymorphisms are associated with cerebrovascular but not with other arterial thrombotic events.  54:1940-1945. 2006
  • Does obesity play a role in functional capacity and inflammation in patients with lupus? Comment on the article by Oeser et al. [1].  54:1705-1706. 2006
  • Effect of folic acid supplementation on the efficacy of metholrexate treatment in rheumatoid arthritis: Comment on the article by Khaanna et al. [5].  54:1708-1709. 2006
  • Systemic lupus erythematosus in a multiethnic US cohort: Clinical features, course, and outcome in patients with late-onset disease.  54:1580-1587. 2006
  • Systemic lupus erythematosus in a multiethnic US cohort: XXXVI. Influence of mannose-binding lectin exon 1 polymorphisms in disease manifestations, course, and outcome.  54:1703-1704. 2006
  • Production of a novel class of polyreactive pathogenic autoantibodies in BXD2 mice causes glomerulonephritis and arthritis.  54:343-355. 2006
  • Expression and occupancy of BAFF-R on B cells in systemic lupus erythematosus.  52:3943-3954. 2005
  • Utility of corticosteroid injection for temporomandibular arthritis in children with juvenile idiopathic arthritis.  52:3563-3569. 2005
  • Synovial fibroblasts promote osteoclast formation by RANKL in a novel model of spontaneous erosive arthritis.  52:3257-3268. 2005
  • Association of single nucleotide Polymorphisms (SNPs) in the vitamin D receptor gene (VDR) with bone mineral density (BMD) in African Americans with early-rheumatoid arthritis (RA)..  52:S118-S119. 2005
  • HLA DRB1 alleles containing the shared epitope are associated with rheumatoid arthritis in African Americans..  52:S149-S150. 2005
  • Editorial: A signal achievement in the treatment of arthritis.  52:2229-2232. 2005
  • Longitudinal patterns in the prevention of osteoporosis in glucocorticoid-treated patients.  52:2485-2494. 2005
  • Synovial intracellular citrullinated proteins colocalizing with peptidyl arginine deiminase as pathophysiologically relevant antigenic determinants of rheumatoid arthritis-specific humoral autoimmunity.  52:2323-2330. 2005
  • Systemic lupus erythematosus in a multiethnic US cohort (LUMINA): XXV. Smoking, older age, disease activity, lupus anticoagulant, and glucocorticoid dose as risk factors for the occurrence of venous thrombosis in lupus patients.  52:2060-2068. 2005
  • Systemic lupus erythematosus in a multiethnic US cohort (LUMINA). XXI. Disease activity, damage accrual, and vascular events in pre- and postmenopausal women.  52:1655-1664. 2005
  • An international cohort study of cancer in systemic lupus erythematosus.  52:1481-1490. 2005
  • Systemic lupus erythematosus in three ethnic groups: XVI. Association of hydroxychloroquine use with reduced risk of damage accrual.  52:1473-1480. 2005
  • Evidence for two phenotypes in the metabolism of methotrexate to 7-hydroxymethotrexate in patients with rheumatoid arthritis.  52:356-358. 2005
  • Folic acid and folinic acid supplements and methotrexate therapy: Comment on the article by Morgan et al. [5] (multiple letters).  52:1338-1339. 2005
  • Opioid use by patients in an orthopedics spine clinic.  52:312-321. 2005
  • Systemic lupus erythematosus in a multiethnic US cohort (LUMINA): XXIII. Baseline predictors of vascular events.  50:3947-3957. 2004
  • The American College of Rheumatology response criteria for systemic lupus erythematosus clinical trials: Measures of overall disease activity.  50:3418-3426. 2004
  • Systemic lupus erythematosus in a multiethnic US cohort (LUMINA): XXII. Predictors of time to the occurrence of initial damage.  50:3177-3186. 2004
  • The effect of folic acid and folinic acid supplements on purine metabolism in methotrexate-treated rheumatoid arthritis.  50:3104-3111. 2004
  • The influence of genetic variation in the HLA-DRB1 and LTA-TNF regions on the response to treatment of early rheumatoid arthritis with methotrexate or etanercept.  50:2750-2756. 2004
  • Associations, populations, and the truth: Recommendations for genetic association studies in Arthritis & Rheumatism.  50:2066-2071. 2004
  • Control of spontaneous B lymphocyte autoimmunity with adenovirus-encoded soluble TACI.  50:1884-1896. 2004
  • Genetic Markers of Treatment Response in Rheumatoid Arthritis.  50:1019-1022. 2004
  • Quality of Care Indicators for Gout Management.  50:937-943. 2004
  • Are US Adults with Arthritis Meeting Public Health Recommendations for Physical Activity?.  50:624-628. 2004
  • Delayed onset of renal disease in mice expressing a human C-reactive protein transgene: Comment on the article by Szalai et al [4] (multiple letters).  50:679-680. 2004
  • Novel Tumor Necrosis Factor α-Regulated Genes in Rheumatoid Arthritis.  50:420-431. 2004
  • Monitoring guidelines for methotrexate-treated rheumatoid arthritis patients: Comment on the article by Yazici et al [1] (multiple letters).  50:2710. 2004
  • Vitamin D Intake Is Inversely Associated With Rheumatoid Arthritis: Results From the Iowa Women's Health Study.  50:72-77. 2004
  • A Novel Polymorphism in the Fcγ Receptor IIB (CD32B) Transmembrane Region Alters Receptor Signaling.  48:3242-3252. 2003
  • The Energy Cost of Adjuvant-Induced Arthritis in Rats.  48:2979-2982. 2003
  • Complementary and alternative medicine use in African Americans with early rheumatoid arthritis (RA)..  48:S250-S250. 2003
  • Health-related quality of life in African Americans with early rheumatoid arthritis..  48:S249-S249. 2003
  • High prevalence of osteopenia/osteoporosis among African Americans with Early Rheumatoid Arthritis..  48:S299-S299. 2003
  • Joint damage occurs early in African Americans with rheumatoid arthritis (RA)..  48:S109-S109. 2003
  • Delayed lupus onset in (NZB × NZW)F1 mice expressing a human C-reactive protein transgene.  48:1602-1611. 2003
  • Screening the genome for rheumatoid arthritis susceptibility genes: A replication study and combined analysis of 512 multicase families.  48:906-916. 2003
  • Dosage of hydroxychloroquine should be based on ideal body weight: Comment on the letter by Alarcón [8] (multiple letters).  48:863-864. 2003
  • Intolerance to caffeine may increase susceptibility to rheumatoid arthritis: Comment on the article by Mikuls et al [3] (multiple letters).  46:3104. 2002
  • Genetic linkage and association of Fcγ receptor IIIA (CD16A) on chromosome 1q23 with human systemic lupus erythematosus.  46:2132-2140. 2002
  • Single-nucleotide polymorphisms in tumor necrosis factor receptor genes: Definition of novel haplotypes and racial/ethnic differences.  46:2045-2050. 2002
  • Genome scan for quantity of hand osteoarthritis: The Framingham Study.  46:946-952. 2002
  • Local production of complement proteins in rheumatoid arthritis synovium.  46:934-945. 2002
  • Coffee, tea, and caffeine consumption and risk of rheumatoid arthritis: Results from the Iowa women's health study.  46:83-91. 2002
  • Coffee, tea, and caffeine consumption and risk of rheumatoid arthritis: results from the Iowa Women's Health Study..  46:83-91. 2002
  • Efficacy of tacrolimus in rheumatoid arthritis patients who have been treated unsuccessfully with methotrexate: A six-month, double-blind, randomized, dose-ranging study.  46:2020-2028. 2002
  • Folic acid and folinic acid supplementation during low-dose methotrexate therapy for rheumatoid arthritis: Comment on the article by van Ede et al [6].  46:1413-1414. 2002
  • High-resolution ultrasound for the study of target joints in rheumatoid arthritis [1] (multiple letters).  46:1969-1970. 2002
  • How frequently and how soon should we screen our patients for the presence of antimalarial retinopathy? [4].  46:561. 2002
  • Systemic lupus erythematosus in three ethnic groups. IX. Differences in damage accrual..  44:2797-2806. 2001
  • Systemic lupus erythematosus in three ethnic groups: IX. Differences in damage accrual.  44:2797-2806. 2001
  • Expression of recombination-activating genes and terminal deoxynucleotidyl transferase and secondary rearrangement of immunoglobulin κ light chains in rheumatoid arthritis synovial tissue.  44:2275-2284. 2001
  • Expression of recombination-activating genes and terminal deoxynucleotidyl transferase and secondary rearrangement of immunoglobulin kappa light chains in rheumatoid arthritis synovial tissue..  44:2275-2284. 2001
  • Defective Fas Ligand-Mediated Apoptosis Predisposes to Development of a Chronic Erosive Arthritis Subsequent to Mycoplasma pulmonis Infection.  44:2146-2159. 2001
  • Defective Fas ligand-mediated apoptosis predisposes to development of a chronic erosive arthritis subsequent to Mycoplasma pulmonis infection..  44:2146-2159. 2001
  • Regulation of tumor necrosis factor α-mediated apoptosis of rheumatoid arthritis synovial fibroblasts by the protein kinase Akt.  44:1555-1567. 2001
  • Regulation of tumor necrosis factor alpha-mediated apoptosis of rheumatoid arthritis synovial fibroblasts by the protein kinase Akt..  44:1555-1567. 2001
  • Systemic lupus erythematosus in three ethnic groups. VIII. Lack of association of glutathione S-transferase null alleles with disease manifestations.  44:981-983. 2001
  • Treatment of chronic sialadenitis in a murine model of Sjögren's syndrome by local fasL gene transfer.  44:964-973. 2001
  • Winners of the 2000 American College of Rheumatology Slide Competition.  44:513-514. 2001
  • Treatment of chronic sialadenitis in a murine model of Sjögren's syndrome by local fasL gene transfer..  44:964-973. 2001
  • Low-binding alleles of fcγ receptor types IIA and IIIA are inherited independently and are associated with systemic lupus erythematosus in hispanic patients.  44:361-367. 2001
  • Recommendations for the prevention and treatment of glucocorticoid-induced osteoporosis: 2001 Update: American College of Rheumatology Ad Hoc Committee on glucocorticoid-induced osteoporosis.  44:1496-1503. 2001
  • Two-year effects of alendronate on bone mineral density and vertebral fracture in patients receiving glucocorticoids: A randomized, double-blind, placebo-controlled extension trial.  44:202-211. 2001
  • Two-year effects of alendronate on bone mineral density and vertebral fracture in patients receiving glucocorticoids: a randomized, double-blind, placebo-controlled extension trial..  44:202-211. 2001
  • Expression of osteopontin messenger RNA and protein in rheumatoid arthritis: Effects of osteopontin on the release of collagenase 1 from articular chondrocytes and synovial fibroblasts.  43:1597-1605. 2000
  • Gene therapy that inhibits nuclear translocation of nuclear factor kappaB results in tumor necrosis factor alpha-induced apoptosis of human synovial fibroblasts..  43:1094-1105. 2000
  • Gene therapy that inhibits nuclear translocation of nuclear factor κB results in tumor necrosis factor α-induced apoptosis of human synovial fibroblasts.  43:1094-1105. 2000
  • Renal failure: A risk factor for methotrexate toxicity.  43:1185-1186. 2000
  • Renal failure: a risk factor for methotrexate toxicity..  43:1185-1186. 2000
  • Folic acid supplementation and methotrexate efficacy: Comment on articles by Schiff, Emery et al, and others [3].  43:2615-2616. 2000
  • Response to methotrexate and reduced mortality in patients with rheumatoid arthritis: Comment on the article by Krause et al [2] (multiple letters).  43:1902-1903. 2000
  • Single-nucleotide polymorphisms of T cell receptor zeta chain in patients with systemic lupus erythematosus..  42:2601-2605. 1999
  • Single-nucleotide polymorphisms of T cell receptor ζ chain in patients with systemic lupus erythematosus.  42:2601-2605. 1999
  • Diminished levels of T cell receptor ζ chains in peripheral blood T lymphocytes from patients with systemic lupus erythematosus.  42:1908-1916. 1999
  • Global statistical tests for comparing multiple outcomes in rheumatoid arthritis trials.  42:1879-1888. 1999
  • Systemic lupus erythematosus in three ethnic groups. IV. Factors associated with self-reported functional outcome in a large cohort study. LUMINA Study Group. Lupus in Minority Populations, Nature versus Nurture..  12:256-266. 1999
  • Specific targeting of activated endothelium in rat adjuvant arthritis with a 99mTc-radiolabeled E-selectin-binding peptide..  42:641-649. 1999
  • Specific targeting of activated endothelium in rat adjuvant arthritis with a 99mTc-radiolabeled e-selectin-binding peptide.  42:641-649. 1999
  • The American College of Rheumatology nomenclature and case definitions for neuropsychiatric lupus syndromes.  42:599-608. 1999
  • The influence of sex on the frequency of erosive disease and extraarticular manifestations in rheumatoid arthritis: Comment on the article by Weyand et al [3].  42:587. 1999
  • Fibromyalgia and physical and emotional trauma: How are they related? Comment on the article by Aaron et al [5] (multiple letters).  42:828-829. 1999
  • Interpreting the results of a segregation analysis of generalized radiographic osteoarthritis: Comment on the article by Felson et al [3].  42:1068-1069. 1999
  • Is Chiari malformation associated with increased levels of substance P and clinical symptoms in persons with fibromyalgia? [1].  42:2731-2736. 1999
  • Murine cytomegalovirus induces a Sjogren's syndrome-like disease in C57B1/6-lpr/lpr mice.  41:2175-2184. 1998
  • Murine cytomegalovirus induces a Sjögren's syndrome-like disease in C57Bl/6-lpr/lpr mice..  41:2175-2184. 1998
  • T cell receptor peptide vaccination in rheumatoid arthritis: A placebo- controlled trial using a combination of V(β)3, V(β)14, and V(β)17 peptides.  41:1919-1929. 1998
  • Immunohistochemical and molecular studies of serotonin, substance P, galanin, pituitary adenylyl cyclase-activating polypeptide, and secretoneurin in fibromyalgic muscle tissue.  41:1689-1694. 1998
  • The effect of methotrexate and 7-hydroxymethotrexate on rat adjuvant arthritis and on urinary aminoimidazole carboxamide excretion.  41:1407-1410. 1998
  • The effect of methotrexate and 7-hydroxymethotrexate on rat adjuvant arthritis and on urinary aminoimidazole carboxamide excretion..  41:1407-1410. 1998
  • Systemic lupus erythematosus in three ethnic groups: I. The effects of HLA class II, C4, and CR1 alleles, socioeconomic factors, and ethnicity at disease onset.  41:1161-1172. 1998
  • Systemic lupus erythematosus in three ethnic groups: II. Features predictive of disease activity early in its course.  41:1173-1180. 1998
  • Evidence for a Mendelian gene in a segregation analysis of generalized radiographic osteoarthritis: The Framingham Study.  41:1064-1071. 1998
  • Arthritis health service utilization among the elderly: The role of urban-rural residence and other utilization factors.  11:177-185. 1998
  • Arthritis health service utilization among the elderly: The role of urban-rural residence and other utilization factors.  11:177-185. 1998
  • Reduction of arthritis and pneumonitis in motheaten mice by soluble tumor necrosis factor receptor.  41:139-149. 1998
  • Reduction of arthritis and pneumonitis in motheaten mice by soluble tumor necrosis factor receptor..  41:139-149. 1998
  • Sexual and physical abuse in women with fibromyalgia: Association with outpatient health care utilization and pain medication usage.  11:102-115. 1998
  • Sexual and physical abuse in women with fibromyalgia: Association with outpatient health care utilization and pain medication usage.  11:102-115. 1998
  • Abnormal pain perception in patients with fibromyalgia: comment on the article by Bendtsen et al..  40:2275-2277. 1997
  • Clinical, laboratory, radiographic, and histopathologic features of methotrexate-associated lung injury in patients with rheumatoid arthritis: A multicenter study with literature review.  40:1829-1837. 1997
  • Symptomatic spinal calcinosis in systemic sclerosis (scleroderma).  40:1892-1895. 1997
  • NFAT binding sites participate in regulation of the CD95 (Fas) ligand promoter in activated T cells..  40:1743-1743. 1997
  • Relative risk and attributable risk needed to interpret 'Factors predictive of infection in cyclophosphamide-treated lupus patients': Comment on the article by Pryor et al.  40:1186. 1997
  • Biologic agents for treating rheumatoid arthritis: Concepts and progress.  40:397-409. 1997
  • Meaningful improvement criteria sets in a rheumatoid arthritis clinical trial.  40:419-425. 1997
  • Perceived physical and emotional trauma as precipitating events in fibromyalgia: Associations with health care seeking and disability status but not pain severity.  40:453-460. 1997
  • Guidelines for folate supplementation in rheumatoid arthritis patients treated with methotrexate: Comment on the guidelines for monitoring drug therapy [1] (multiple letters).  40:391-392. 1997
  • Nutrient intake patterns, body mass index, and vitamin levels in patients with rheumatoid arthritis.  10:9-17. 1997
  • Nutrient intake patterns, body mass index, and vitamin levels in patients with rheumatoid arthritis.  10:9-17. 1997
  • Slow progression of joint damage in early rheumatoid arthritis treated with cyclosporin A or methotrexate: Comment on the article by Pasero et al [3].  40:791. 1997
  • HLA-DRB1 genes and disease severity in rheumatoid arthritis.  39:1802-1807. 1996
  • Low-dose corticosteroids in rheumatoid arthritis: A meta-analysis of their moderate-term effectiveness.  39:1818-1825. 1996
  • Reactive arthritis in patients attending an urban sexually transmitted diseases clinic.  39:1172-1177. 1996
  • Workshop on chronic pain, pain control, and patient outcomes in rheumatoid arthritis and osteoarthritis.  39:357-362. 1996
  • Psychiatric diagnoses in patients with fibromyalgia are related to health care-seeking behavior rather than to illness.  39:436-445. 1996
  • Early undifferentiated connective tissue disease. IV. Musculoskeletal manifestations in a large cohort of patients with undifferentiated connective tissue diseases compared with cohorts of patients with well-established connective tissue diseases: Followup analyses in patients with unexplained polyarthritis and patients with rheumatoid arthritis at baseline.  39:403-414. 1996
  • Methotrexate patient education: A quality improvement study.  9:216-222. 1996
  • Methotrexate patient education: A quality improvement study.  9:216-222. 1996
  • Rheumatoid arthritis lung disease: Determinants of radiographic and physiologic abnormalities.  39:1711-1719. 1996
  • Use of sensitive assays to detect soluble Fas in patients with systemic lupus erythematosus: comment on the article by Knipping et al and the article by Goel et al..  39:1611-1612. 1996
  • Development of an observation method for assessing pain behaviors in children with juvenile rheumatoid arthritis.  38:1142-1151. 1995
  • Double‐blind, placebo‐controlled multicenter trial using chimeric monoclonal anti‐cd4 antibody, cm‐t412, in rheumatoid arthritis patients receiving concomitant methotrexate.  38:1581-1588. 1995
  • Fibromyalgia in women.  38:926-938. 1995
  • Identification of patient subsets among those presumptively diagnosed with, referred, and/or followed up for systemic lupus erythematosus at a large tertiary care center.  38:1475-1484. 1995
  • Improved methotrexate patient information.  38:874-875. 1995
  • Interleukin‐2 diphtheria fusion protein (dab486il‐2) in refractory rheumatoid arthritis a double‐blind, placebo‐controlled trial with open‐label extension.  38:1177-1186. 1995
  • Photoexacerbation of cutaneous lupus erythematosus due to ultraviolet a emissions from a photocopier.  38:1152-1156. 1995
  • Progressive joint destruction in a human immunodeficiency virus‐infected patient with rheumatoid arthritis.  38:1328-1332. 1995
  • Receptors for immunoglobulin g molecular diversity and implications for disease.  38:306-314. 1995
  • Reply.  38:297-298. 1995
  • Rheumatoid synovial fibroblast adhesion to human articular cartilage.  38:1694-1700. 1995
  • Stress fractures in rheumatoid arthritis: comment on the article by wei.  38:1025-1025. 1995
  • Usefulness of the american college of rheumatology recommendations for liver biopsy in methotrexate‐treated rheumatoid arthritis patients.  38:1115-1119. 1995
  • Winners of the 1995 ACR slide competition and future plans for the clinical slide collection on the rheumatic diseases.  38:1733-1734. 1995
  • Autoimmune disease. a problem of defective apoptosis.  37:1415-1420. 1994
  • Ciprofloxacin reactions mimicking lupus flares.  37:1112-1113. 1994
  • HIP Osteonecrosis Secondary to the Administration of Corticosteroids for Feigned Bronchial Asthma.  37:139-141. 1994
  • Issues in meta‐analysis: An overview.  7:156-160. 1994
  • Leucovorin Versus Folic Acid in the Treatment of Methotrexate Toxicity: Comment on the Article by Shiroky et a1.  37:444-444. 1994
  • Methotrexate for Rheumatoid Arthritis.  37:316-328. 1994
  • Pain behavior of rheumatoid arthritis patients enrolled in experimental drug trials.  7:64-68. 1994
  • Reply.  37:1830-1830. 1994
  • T Cell Influence on Superantigen‐Induced Arthritis in MRL‐lpr/lpr Mice.  37:113-124. 1994
  • Treatment of refractory rheumatoid arthritis with a chimeric ANTI‐CD4 monoclonal antibody.  37:834-838. 1994
  • On women's issues..  6:115-116. 1993
  • Analysis of immunoglobulin gamma heavy chain expression in synovial tissue of a patient with rheumatoid arthritis.  36:631-641. 1993
  • Biopsychosocial contributions to the management of arthritis disability.  36:885-889. 1993
  • Comparison of naproxen and acetaminophen in a two‐year study of treatment of osteoarthritis of the knee.  36:1196-1206. 1993
  • Degradation of human articular cartilage by neutrophils in synovial fluid.  36:51-58. 1993
  • Determinants of serious liver disease among patients receiving low‐dose methotrexate for rheumatoid arthritis.  36:329-335. 1993
  • Dietary intake and circulating vitamin levels of rheumatoid arthritis patients treated with methotrexate.  6:4-10. 1993
  • Dietary intake and circulating vitamin levels of rheumatoid arthritis patients treated with methotrexate.  6:4-10. 1993
  • Insufficiency fracture of the distal ulna presenting as cellulitis.  36:1027-1028. 1993
  • Introduction.  6:169-170. 1993
  • Methotrexate and sulfasalazine combination therapy: Is it worth the risk?.  36:281-282. 1993
  • Neural substrates of pain and analgesia.  6:171-177. 1993
  • Nonperipheral accelerated nodulosis in a methotrexate‐treated rheumatoid arthritis patient.  36:132-133. 1993
  • On women's lssues.  6:115-116. 1993
  • Pain measurement in arthritis.  6:178-186. 1993
  • Pain measurement in arthritis.  6:178-186. 1993
  • Radiographic assessment of disease progression in rheumatoid arthritis patients enrolled in the cooperative systematic studies of the rheumatic diseases program randomized clinical trial of methotrexate, auranofin, or a combination of the two.  36:1364-1369. 1993
  • Reply.  36:1757-1758. 1993
  • Use of a chimeric monoclonal anti‐CD4 antibody in patients with refractory rheumatoid arthritis.  36:307-318. 1993
  • Use of self ‐ administered joint counts in the evaluation of rheumatoid arthritis patients.  6:78-81. 1993
  • A rheumatoid factor from a normal individual encoded by VH2 and VkII gene segments.  35:900-904. 1992
  • Challenges facing psychologists in arthritis research. Reflections on a tenth anniversary.  5:1-2. 1992
  • Comparison of auranofin, methotreaxate, and the combination of both in the treatment of rheumatoid arthritis. A controlled clinical trial.  35:259-269. 1992
  • Efficacy and safety of 10‐deazaaminopterin in the treatment of rheumatoid arthritis: A one‐year continuation, double‐blind study.  35:1318-1321. 1992
  • Multiple testing in a rheumatoid arthritis trial. Statistical comparison of two therapies with respect to several endpoints.  5:70-73. 1992
  • Observation of pain behavior in rheumatoid arthritis patients during physical examination. Relationship to disease activity and psychological variables.  5:49-56. 1992
  • Reply.  35:1401-1402. 1992
  • The immunoglobulin kappa light chain repertoire expressed in the synovium of a patient with rheumatoid arthritis.  35:905-913. 1992
  • A comparison of the full and short versions of the arthritis impact measurement scales.  4:168-173. 1991
  • A comparison of the full and short versions of the arthritis impact measurement scales.  4:168-173. 1991
  • Arthritis care and research. A quality/needs assessment.  4:141-142. 1991
  • Colchicine and gout.  34:782-786. 1991
  • Combination of disease-modifying antirheumatic drugs in the treatment of rheumatoid arthritis. A survey of Alabama rheumatologists.  4:48-51. 1991
  • Combination of disease‐modifying antirheumatic drugs in the treatment of rheumatoid arthritis A survey of alabama rheumatologists.  4:48-51. 1991
  • Enhanced CD3‐mediated T lymphocyte proliferation in patients with systemic lupus erythematosus.  34:459-467. 1991
  • Insufficiency fractures of the distal tibia misdiagnosed as cellulitis in three patients with rheumatoid arthritis.  34:912-915. 1991
  • Prosthetic joint infections. A role for prophylaxis.  34:110-117. 1991
  • Reply.  34:120-121. 1991
  • Rheumatoid arthritis patients and clinical drug trials A case‐control study.  4:22-26. 1991
  • Tenidap, in contrast to several available nonsteroidal antiinflammatory drugs, potently inhibits the release of activated neutrophil collagenase.  34:211-216. 1991
  • The American College of Rheumatology criteria for the classification and reporting of osteoarthritis of the hip.  34:505-514. 1991
  • Working for arthritis care and research. The editorial office and the AHPA membership.  4:61-62. 1991
  • Achieving consensus on an algorithm for the treatment of rheumatoid arthritis with Methotrexate.  3:53-58. 1990
  • Achieving consensus on an algorithm for the treatment of rheumatoid arthritis with methotrexate.  3:53-57. 1990
  • Comment on the article by Morgan et al (Reply).  33:1447. 1990
  • Comment on the article by calin et al.  33:1600-1600. 1990
  • Correlation of serologic indicators of inflammation with effectiveness of nonsteroidal antiinflammatory drug therapy in rheumatoid arthritis.  33:19-28. 1990
  • Intravenous immunoglobulin therapy in systemic lupus erythematosus‐associated thrombocytopenia.  33:1233-1239. 1990
  • Letter to the editor (I).  3:104-105. 1990
  • Letter to the editor (I).  3:104-105. 1990
  • Letters.  3:104-105. 1990
  • Ligand‐dependent release of active neutrophil collagenase.  33:228-234. 1990
  • Lupus‐inducing drugs alter the structure of supercoiled circular dna domains.  33:366-374. 1990
  • Lysis of fibrillar collagen by neutrophils in synovial fluid. A Role for Surface‐Bound Immunoglobulins.  33:1333-1339. 1990
  • Monoclonal antibody 6b6.6 defines a cross‐reactive kappa light chain idiotope on human monoclonal and polyclonal rheumatoid factors.  33:187-198. 1990
  • Prognosis in systemic lupus erythematosus.  33:37-48. 1990
  • Reply.  33:1447-1447. 1990
  • Rheumatology algorithms for primary care physicians.  3:71-77. 1990
  • Rheumatology algorithms for primary care physicians.  3:71-77. 1990
  • Structural characterization of the second major cross‐reactive idiotype group of human rheumatoid factors. Association with the VH4 Gene Family.  33:1347-1360. 1990
  • Suppression of rheumatoid factor production by methotrexate in patients with rheumatoid arthritis: Evidence for differential influences of therapy and clinical status on IgM and IgA rheumatoid factor expression.  33:1156-1161. 1990
  • The American College of Rheumatology criteria for the classification and reporting of osteoarthritis of the hand.  33:1601-1610. 1990
  • The effect of folic acid supplementation on the toxicity of low‐dose methotrexate in patients with rheumatoid arthritis.  33:9-18. 1990
  • Toxic response to topical fluorouracil in two rheumatoid arthritis patients receiving low‐dose, weekly methotrexate.  33:303-304. 1990
  • Methotrexate in rheumatoid arthritis. Toxic effects as the major factor in limiting long-term treatment..  32:671-676. 1989
  • Adherence with treatment regimens among adult rheumatoid arthritis patients: Current status and future directions.  2. 1989
  • Adherence with treatment regimens among adult rheumatoid arthritis patients: Current status and future directions.  2:A33-A39. 1989
  • An antibody that inhibits in vitro bone marrow proliferation in a patient with systemic lupus erythematosus and aplastic anemia.  32:901-905. 1989
  • Arthritis treatment, adherence, and behavioral medicine.  2. 1989
  • Arthritis treatment, adherence, and behavioral medicine.  2:A84-A86. 1989
  • Coccidioidomycosis of bone: A sequela of desert rheumatism.  32:1608-1610. 1989
  • Comment on the article by Furst et al.  32:1631-1632. 1989
  • Comment on the article by Tomana et al.  32:235-236. 1989
  • Folic acid treatment in methotrexate‐treated rheumatoid arthritis patients: comment on the article by Furst and Kremer.  32:113-114. 1989
  • High‐Dose, pulse intravenous methylprednisolone enhances fcγ receptor–mediated mononuclear phagocyte function in systemic lupus erythematosus.  32:717-725. 1989
  • Impotence in three rheumatoid arthritis patients treated with methotrexate.  32:1341-1342. 1989
  • Intraarticular corticosteroid injections: Should we rest the joints?.  2:70-74. 1989
  • Intraarticular corticosteroid injections: Should we rest the joints?.  2:70-74. 1989
  • Involvement of the cervical spine in rheumatoid arthritis.  32:652-659. 1989
  • Predicting individual differences in pain and functional impairment among patients with rheumatoid arthritis.  32:851-858. 1989
  • Psychosocial factors and disease outcomes in rheumatoid arthritis: Old problems, new solutions, and a future agenda.  32:1611-1614. 1989
  • Radiologic assessment as an outcome measure in rheumatoid arthritis.  32:221-229. 1989
  • Secretion of antibodies to types I and II collagen by synovial tissue cells in patients with rheumatoid arthritis.  32:1087-1092. 1989
  • The process of training rheumatology research assistants.  2:83-85. 1989
  • inflammatory myopathy and acquired immunodeficiency syndrome.  32:475-479. 1989
  • Radiographic assessment and psychologic variables as predictors of pain and functional impairment in osteoarthritis of the knee or hip..  31:204-209. 1988
  • The use of magnetic resonance imaging (MRI) in patients with rheumatoid arthritis and subluxations of the cervical spine..  31:304. 1988
  • Abnormal glycosylation of serum igg from patients with chronic inflammatory diseases.  31:333-338. 1988
  • Comment on the article by breedveld et al.  31:304-304. 1988
  • Interstitial pneumonitis in antinuclear antibody–negative systemic lupus erythematosus: a new clinical manifestation and possible association with anti–ro (ss‐a) antibodies.  31:545-548. 1988
  • Letters.  1:65-66. 1988
  • A low molecular weight, heat‐labile factor enhances neutrophil fc receptor–mediated lysosomal enzyme release and phagocytosis.  30:1006-1014. 1987
  • Airways disease in rheumatoid arthritis patients.  30:249-256. 1987
  • Analyses of hla linkage in white families with multiple cases of seropositive rheumatoid arthritis.  30:1115-1123. 1987
  • Association of a 9.2‐kilobase pvu ii class i major histocompatibility complex restriction fragment length polymorphism with ankylosing spondylitis.  30:894-900. 1987
  • Deletion of C4A genes in patients with systemic lupus erythematosus.  30:1015-1022. 1987
  • Effects of psychological therapy on pain behavior of rheumatoid arthritis patients. treatment outcome and six‐month followup.  30:1105-1114. 1987
  • Folate status of rheumatoid arthritis patients receiving long‐term, low‐dose methotrexate therapy.  30:1348-1356. 1987
  • Lack of association between hla–dr2 and clinical response to methotrexate in patients with rheumatoid arthritis.  30:218-220. 1987
  • Review of the national arthritis advisory board symposium, “molecular biology: its potential for advancing rheumatology research”.  30:1191-1194. 1987
  • The assessment of pain in rheumatoid arthritis.  30:36-43. 1987
  • The interaction of antibody/dna immune complexes with complement.  30:176-185. 1987
  • Abnormal immunoglobulin and rheumatoid factor synthesis by blood lymphocytes in patients with primary Sjögren's syndrome.  29:1446-1455. 1986
  • DR2 positivity and response to methotrexate in rheumatoid arthritis.  29:151-151. 1986
  • Development of criteria for the classification and reporting of osteoarthritis: Classification of osteoarthritis of the knee.  29:1039-1049. 1986
  • Elevated MMPI scores for hypochondriasis, depression, and hysteria in patients with rheumatoid arthritis reflect disease rather than psychological status.  29:1456-1466. 1986
  • Molecular forms of IgA rheumatoid factor in serum and synovial fluid of patients with rheumatoid arthritis.  29:1194-1202. 1986
  • Comment on letter by Alarcón et al.  28:1439-1440. 1985
  • Comparison of low‐dose oral pulse methotrexate and placebo in the treatment of rheumatoid arthritis. A Controlled Clinical Trial.  28:721-730. 1985
  • Double‐blind, multicenter controlled trial comparing topical dimethyl sulfoxide and normal saline for treatment of hand ulcers in patients with systemic sclerosis.  28:308-314. 1985
  • Etiopathogenesis of the rheumatoid arthritis–like disease in MRL/1 mice. I. The histomorphologic basis of joint destruction.  28:529-536. 1985
  • HLA‐Bw35 and gold toxicity in rheumatoid arthritis.  28:236-237. 1985
  • IgA rheumatoid factor synthesis by dissociated synovial cells. Characterization and relationship to IgM rheumatoid factor synthesis.  28:1219-1227. 1985
  • In vitro IgM and IgM rheumatoid factor production and response to remittive agents in rheumatoid arthritis.  28:356-357. 1985
  • Production of immunoglobulin and rheumatoid factor by lymphoid cells in rheumatoid pericardium.  28:1071-1074. 1985
  • Pure red cell aplasia and protein‐losing enteropathy in a patient with systemic lupus erythematosus.  28:1059-1061. 1985
  • Azathioprine versus d‐penicillamine in rheumatoid arthritis patients who have been treated unsuccessfully with gold.  27:721-727. 1984
  • Bullous lupus erythematosus rash worsened by dapsone.  27:1071-1072. 1984
  • Dr Antigens and Gold Toxicity in white rheumatoid arthritis patients.  27:601-605. 1984
  • Rheumatoid arthritis and small airways function.  27:728-736. 1984
  • Rheumatoid myositis.  27:737-743. 1984
  • American rheumatology: markings.  26:548-552. 1983
  • An autopsy study of the prevalence of monosodium urate and calcium pyrophosphate dihydrate crystal deposition in first metatarsophalangeal joints.  26:1522-1524. 1983
  • Human alpha‐interferon enhances in vitro igm rheumatoid factor synthesis by lymphocytes from normal subjects and rheumatoid arthritis patients.  26:1091-1097. 1983
  • Seronegative rheumatoid arthritis and b7‐creg: disparate results.  26:1412-1413. 1983
  • Systemic lupus erythematosus, gout, and Paget's disease.  26:238-238. 1983
  • A serial study of splenic reticuloendothelial system fc receptor functional activity in systemic lupus erythematosus.  25:48-54. 1982
  • Differential patterns of in vitro IgM rheumatoid factor synthesis in seronegative and seropositive rheumatoid arthritis.  25:150-155. 1982
  • Seronegative rheumatoid arthritis..  25:502-507. 1982
  • Acute corticosteroid-induced depression of renal function in systemic lupus erythematosus (SLE): Association with decreased renal prostaglandin synthesis.  24:300. 1981
  • A sensitive radioimmunoassay for quantitation of igm rheumatoid factor.  23:302-308. 1980
  • Comparative effects of aspirin and ibuprofen in the management of systemic lupus erythematosus.  23:1401-1404. 1980
  • Dermal fibrosis in spinal cord injury patients.  23:1312-1317. 1980
  • Dynamics of renal function in lupus nephritis: predictive value and implications of drug-induced transient changes.  23:703. 1980
  • Enhanced in vitro synthesis of igm rheumatoid factor in rheumatoid arthritis.  23:985-992. 1980
  • Great reduction in renal function associated with cimetidine.  23:614-615. 1980
  • Lung injury due to gold treatment.  23:351-354. 1980
  • Acute corticosteroid-induced depression of renal function in systemic lupus erythematosus.  22:629-630. 1979
  • Apparent acute renal failure associated with therapeutic aspirin and ibuprofen administration.  22:281-285. 1979
  • Clinical efficacy of high dose intravenous methylprednisolone pulse therapy in systemic lupus erythematosus.  22:629. 1979
  • Presumptive autonephrectomy in scleroderma.  22:305-305. 1979
  • The infectious etiology of rheumatoid arthritis..  21:531-538. 1978
  • Aspirin and Delayed Type Hypersensitivity.  20:1174-1178. 1977
  • Gold‐Induced Thrombocytopenia: Response to Vincristine?.  20:1288-1289. 1977
  • Antibodies to native and denatured collagens in sera of patients with rheumatoid arthritis.  19:613-617. 1976
  • Salicylate hepatotoxicity in patients with juvenile rheumatoid arthritis.  16:1-9. 1973
  • The pathogenesis of hyperuricemia and gout in sickle cell anemia.  13:846-848. 1970
  • Ankylosing spondylitis with widespread arteritis.  9:737-745. 1966